- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT06459648
Badanie dotyczące zapobiegania chronicznej migrenie poprzez przewidywanie odpowiedzi na leczenie przeciwciałami anty-CGRP (PREDI-CGRP)
Badanie przewidywania lub odpowiedź na leczenie przeciwciałami monoklonalnymi anty-CGRP w migrenie
Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The study consists of an initial visit coinciding with the start of treatment, a subsequent visit after 6 months of treatment and finally another after 12 months, coinciding with the end of treatment. In case of worsening after suspension, a clinical visit will be carried out at the time of worsening to evaluate the reintroduction of the drug and in case of reintroduction, a visit will be carried out after 3 months. If patients do not worsen, a visit will be made 6 months after completing treatment.
At each visit, demographic and clinical variables will be collected. In addition, 3 blood tests will be performed corresponding to the beginning of treatment, after 6 months and a month and a half from the last infiltration. Likewise, a brain MRI will be obtained prior to the start of treatment. These blood samples and neuroimaging data will be processed for subsequent analysis.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Aragon
-
Zaragoza, Aragon, Hiszpania, 50009
- Hospital Clínico Universitario Lozano Blesa
-
-
Basque Country
-
Donostia / San Sebastian, Basque Country, Hiszpania, 20014
- Hospital Universitario Donostia
-
-
Cantabria
-
Santander, Cantabria, Hiszpania, 39008
- Hospital Universitario Marqués de Valdecilla
-
-
Castille and León
-
Valladolid, Castille and León, Hiszpania, 47010
- Hospital Clínico Universitario de Valladolid
-
-
Catalonia
-
Barcelona, Catalonia, Hiszpania, 08035
- Hospital Universitari Vall d'Hebron Research Institute
-
-
Madrid
-
Madrid, Madrid, Hiszpania, 28006
- Hospital Universitario de La Princesa
-
-
Valencia
-
Valencia, Valencia, Hiszpania, 46026
- Hospital Universitario Politécnico La Fe
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Patients aged between 18 and 65 years with a diagnosis of episodic or chronic migraine who, at the discretion of their neurologist and according to clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or its receptor (Erenumab) be included. These patients will come from 7 Headache Units in Spain belonging to the following hospitals:
- La Princesa University Hospital
- Vall d'Hebron University Hospital
- Marqués de Valdecilla University Hospital
- Valladolid University Clinical Hospital
- Donostia University Hospital
- Lozano Blesa University Clinical Hospital
- La Fe Polytechnic University Hospital
Opis
Inclusion Criteria:
- Patients aged between 18 and 65 years.
- Caucasian ethnicity.
- Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).
- Have at least one year of history of migraine.
- Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.
- Patients able to describe their clinical situation and the characteristics of their headache.
- Grant your informed consent.
Exclusion Criteria:
- Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.
- Neurological focus in the examination.
- Pregnancy or breastfeeding period.
- Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.
- Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.
- Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Patients with migraine under treatment with monoclonal antibodies against CGRP
Patients with diagnosis of episodic or chronic migraine who, under the criteria of their neurologist and according to the clinical practice guidelines and standard of care, receive treatment with monoclonal antibodies against CGRP (Galcanezumab, Fremanezumab, Eptinezumab) or else its receptor (Erenumab) will be included. |
The patient will keep a record of the presence/absence of headache, average intensity, and need for acute medication. Each patient performs different scales that measure the impact of the migraine on their daily life as well as the disability it may be causing. In turn, each patient performs different scales that measure associated comorbidities such as depression, anxiety or insomnia. Erenumab, Galcenazumeb, Fremanezumab, Eptinezumab |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Biomarkers of positive initial response to monoclonal antibodies
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Establish clinical, demographic, transcriptomic, genetic, molecular and/or radiological characteristics that allow predicting a positive initial response to monoclonal antibodies (biomarkers of therapeutic response). |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Sustained response factors
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To analyze sustained response factors at the sociodemographic, clinical, transcriptomic, genetic, molecular and/or radiological level after the suspension of anti-CGRP drugs. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Sustained response after discontinuation of the anti-CGRP antibody
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To quantify the proportion of patients who present a sustained response after discontinuation of the anti-CGRP antibody. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Non-maintained pharmacological response relation with biomarkers
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To characterize whether the non-maintained pharmacological response is related to the variables previously characterized as predictors of chronicity. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Time until relapse after discontinuation of the anti-CGRP antibody
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To determine the time until relapse after discontinuation of the anti-CGRP monoclonal antibody in those patients who, having presented a positive initial response, discontinue it. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
|
Biomarkers of patients with high-frequency episodic migraine and chronic migraine
Ramy czasowe: From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
To validate possible transcriptomic, genetic, molecular and/or radiological characteristics that allow differentiation between patients with high-frequency episodic migraine and chronic migraine in a national multicenter cohort. |
From the beginning of treatment, which is the initial visit, to 18 months of follow-up
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Ana Beatriz Gago Veiga, Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- PI 23- 3054
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Individual participant data (IPD) will not be shared with other researchers. This decision is based on data protection and confidentiality requirements in accordance with applicable European and national regulations (including GDPR). Given that this is a multicentre observational study conducted in routine clinical practice, access to IPD is restricted to the study investigators for the purposes of the predefined analyses.
Any potential secondary use of the dataset would only be considered in fully anonymized form and subject to prior ethical approval and compliance with applicable data protection legislation.
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .